MedTrace Logo

Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer

NCT00032058 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2011-02-21

No results posted yet for this study

Summary

RATIONALE: Imaging procedures such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) may improve the ability to detect the extent of prostate cancer. It is not yet known if MRI combined with MRSI is more effective than MRI alone in detecting the extent of prostate cancer.

PURPOSE: Diagnostic trial to compare the effectiveness of combining MRI with MRSI to that of MRI alone in determining the extent of prostate cancer in patients who are scheduled to undergo surgery to remove the prostate gland.

Conditions

Interventions

PROCEDURE

magnetic resonance imaging

PROCEDURE

magnetic resonance spectroscopic imaging

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • American College of Radiology Imaging Network

    lead NETWORK

Principal Investigators

  • Jeffrey Weinreb, MD · Yale University

Study Design

Purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00032058 on ClinicalTrials.gov